

Application No.: 09/771,312

Docket No.: 511582000100

**REMARKS**

Claims 1-48 are pending. Claims 1-11, 13, 16-38 and 40-48 have been canceled without prejudice. Applicants reserve the right to pursue the subject matter of these canceled claims in one or more divisional applications. Applicants have amended claims 12, 14, 15 and 39, to clarify the subject matter regarded as the invention. These amendments have not been made for purposes of patentability.

**Restriction Requirement**

The Office has imposed a 15-way restriction requirement on the pending set of claims. In response, Applicants elect to prosecute Group II without traverse, which comprises claims 11-15 and 39 (in part), as specifically drawn to an isolated 84P2A9-related protein, classified in class 530, subclass 350 as it relates to the amino acid sequence provided in SEQ ID NO: 2.

Application No.: 09/771,312


Docket No.: 511582000100

**CONCLUSION**

Applicants have addressed each and every issue raised in the outstanding Restriction Requirement. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below. In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 511582000100. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 24, 2005

Respectfully submitted,

By   
James J. Mullen III, Ph.D.Registration No.: 44,957  
MORRISON & FOERSTER LLP  
3811 Valley Centre Drive, Suite 500  
San Diego, California 92130  
(858) 720-7940